Together, we reach far beyond the skin
Putting innovation into practice
with an extensive global portfolio of treatments in medical dermatology
Lifting the burden of disease
for nearly 100 million people who rely on our medicines every year
Shaping the future of what’s next
in partnership with healthcare organizations, scientists and patient groups
PRESS RELEASE
LEO Pharma delivers 9% revenue growth at CER in Q1 2026 and strengthens innovation pipeline
In Q1 2026, LEO Pharma delivered robust revenue growth, driven by the dermatology portfolio, and improved profitability while significantly increasing commercial investments to support the global roll-out of Anzupgo® and the addition of Spevigo® to the portfolio.
Ballerup, Denmark, May 5, 2026
Learn moreMORE NEWS
- May 05 2026 LEO Pharma delivers 9% revenue growth at CER in Q1 2026 and strengthens innovation pipeline
- Apr 30 2026 LEO Pharma bolsters rare skin disease focus through acquisition of Replay gene therapy platform
- Apr 17 2026 LEO Pharma expands its psoriasis portfolio in China with NMPA approval of Enstilar®
ANNUAL REPORT 2025
LEO Pharma delivers 10% revenue growth in 2025 and more than doubles adjusted EBITDA margin
In 2025, LEO Pharma delivered a third consecutive year of double‑digit revenue growth (CER), at the upper end of guidance, and achieved a significant improvement in profitability, returning to positive net profit and free cash flow.
CAREER
Discover how we innovate collectively.
For us, collaborating innovatively means continuously enhancing and expanding what's achievable for one another, our company, and our patients.